Imetelstat: a first-in-class telomerase inhibitor

A unique molecule targeting a hallmark of cancer

2019 annual meeting of stockholders

Event details are available

A transformative approach

Disease-modifying potential in hematologic malignancies

Together we can make a difference in patients’ lives

Partnering is a key to our success

A visionary history

Creating a legacy of bold innovation